The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics Inc. released newly published data in the Journal of Clinical Oncology showing clinical outcomes for the combination of ficerafusp alfa and pembrolizumab in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC).
A more extensive analysis of the data points to deep and lasting responses, as well as promising survival results, particularly in a patient population with high unmet medical needs. The findings may signal a step forward in targeted treatment strategies for these challenging cases.
Bicara Therapeutics is set to present its first quarter 2026 financial results and business update on May 11 via a public webcast, according to a recent announcement. The scheduled event follows ongoing efforts by the company to advance its product pipeline. The company has not provided further details on its upcoming financial disclosures.